healthy subjects
Conditions
Interventions
Group 1: 1) Sequence of measurements
1. No moduation
2. Modulation through focus
3. Modulation through distraction
4. Modulation through increased expectancy
2) Increased expectancy with given more p
Sponsors
Neurologische Klinik, BG Universitätsklinikum Bergmannsheil gGmbH
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: - no exclusion criteria present - declaration of consent
Exclusion criteria
Exclusion criteria: - Age 45 - Lack of informed consent - Average pain intensity in the last 4 weeks > 2 (NRS 0-10) - Current pain intensity > 0 (NRS 0-10) - Insufficient knowledge of German or other communication problems - Neuropathies, radiculopathies or nerve lesions - Painful condition of one or more extremities - Other neuropathic pain syndromes (e.g. polyneuropathy) - Treatment with topical local anaesthetics in the last 6 weeks - Treatment with topical capsaicin in the last 6 months - Epilepsy treated with anticonvulsants (carbamazepine, gabapentin, oxcarbazepine, pregabalin, valproate, etc.) - Psychiatric illness (e.g. severe depression, bipolar disorder, anxiety disorder) treated with antidepressants with proven effect on neuropathic pain (tricyclic AD, e.g. amitriptyline; SNRI, e.g. duloxetine, venlafaxine; SSRI, e.g. citalopram) - Psychiatric illness (e.g. severe depression, bipolar disorder, anxiety disorder) treated with anticonvulsants - Other severe systemic or focal CNS affection (e.g. stroke, spinal cord lesion, syringomyelia) - Other central or peripheral neurological diseases (e.g. Parkinson's disease, polyneuropathy, multiple sclerosis, dementia) - Peripheral arterial occlusive disease (up to stage Fontaine I) - Severe cognitive or psychiatric impairment - Cardiac pacemaker - Serious internal diseases - Diabetes mellitus - Existing long-term medication - Dependence on or abuse of substances (e.g. drugs, medication)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in N1P1-amplitudes, N1-latencies and evoked pain intensity of PREP under different attentional modulation compared to measurements without modulation | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of N1P1-amplitudes, N1-latencies and evoked pain intensity of PREP of focus and distraction | — |
Countries
Germany
Contacts
Public ContactOliver Höffken
Neurologische Klinik, BG Universitätsklinikum Bergmannsheil gGmbH
Outcome results
None listed